Nektar Therapeutics (NKTR) Change in Acquisitions & Divestments (2010 - 2026)

Nektar Therapeutics' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $101.5 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 46.4% year-over-year to $101.5 million; the TTM figure through Mar 2026 stood at $316.8 million (up 11.09% YoY), while the FY2025 annual figure was $284.7 million, down 16.36% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $101.5 million, up from $92.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $238.4 million in Q2 2022, with the low at -$626.4 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $92.0 million (2025), against an average of $42.7 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 126.34% in 2022, while the deepest fall reached 9789.47% in 2022.
• Nektar Therapeutics' Change in Acquisitions & Divestments stood at -$626.4 million in 2022, then gained by 21.08% to -$494.4 million in 2023, then soared by 113.17% to $65.1 million in 2024, then soared by 41.28% to $92.0 million in 2025, then rose by 10.32% to $101.5 million in 2026.
• Business Quant data shows NKTR's Change in Acquisitions & Divestments at $101.5 million in Q1 2026, $92.0 million in Q4 2025, and $54.8 million in Q3 2025.